

1 Nanopore Metagenomic Sequencing for Detection and Characterization of SARS-CoV-2 in Clinical  
2 Samples

3  
4 **Nick P.G. Gauthier<sup>1</sup>, Cassidy Nelson<sup>2</sup>, Michael B. Bonsall<sup>2</sup>, Kerstin Locher<sup>3,4</sup>, Marthe Charles<sup>3,4</sup>,**  
5 **Clayton MacDonald<sup>3,4</sup>, Mel Krajden<sup>4,5</sup>, Samuel D. Chorlton<sup>4,6\*</sup>, Ameer R. Manges<sup>5,7\*</sup>**

6 <sup>1</sup>Department of Microbiology and Immunology, University of British Columbia, Vancouver, British  
7 Columbia, Canada

8 <sup>2</sup>Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford, United  
9 Kingdom

10 <sup>3</sup>Division of Medical Microbiology, Vancouver General Hospital, Vancouver, British Columbia, Canada

11 <sup>4</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British  
12 Columbia, Canada

13 <sup>5</sup>British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada

14 <sup>6</sup>BugSeq Bioinformatics Inc, Vancouver, British Columbia, Canada

15 <sup>7</sup>School of Population and Public Health, University of British Columbia, Vancouver, British Columbia,  
16 Canada

17

18 **\*Denotes equal contribution**

19 **Corresponding authors:**

20 Samuel D. Chorlton, MD, [sam@bugseq.com](mailto:sam@bugseq.com)

21 Ameer R. Manges, MPH, PhD, [amee.manges@ubc.ca](mailto:amee.manges@ubc.ca)

22

23 **Running Title:** Nanopore Metagenomic Sequencing of SARS-CoV-2

24

25 **Key words:** Nanopore, Metagenomic, SARS-CoV-2, Coronavirus, Molecular epidemiology, Diagnostic,  
26 Sequence-independent single-primer amplification, NGS

## 27 **Abstract**

28

29 The COVID-19 pandemic has underscored the need for rapid novel diagnostic strategies to detect and  
30 characterize pathogens from clinical specimens. The MinION sequencing device allows for rapid, cost-  
31 effective, high-throughput sequencing; useful features for translation to clinical laboratory settings.  
32 Metagenomic Next-Generation Sequencing (mNGS) approaches provide the opportunity to examine the  
33 entire genomic material of a sample; allowing for detection of emerging and clinically relevant pathogens  
34 that may be missed in targeted assays. Here we present a pilot study on the performance of Sequence-  
35 Independent Single Primer Amplification (SISPA) to amplify RNA randomly for the detection and  
36 characterization of SARS-CoV-2. We designed a classifier that corrects for barcode crosstalk between  
37 specimens. Our assay yielded 100% specificity overall and 95.2% sensitivity for specimens with a RT-  
38 qPCR cycle threshold value less than 30. We assembled 10 complete (>95% coverage at 20x depth), and  
39 one near-complete (>80% coverage at 20x depth) genomes from 20 specimens that were classified as  
40 positive by mNGS. We characterized these genomes through phylogenetic analysis and found that 10/11  
41 specimens from British Columbia had a closest relative to another British Columbian specimen. Of five  
42 samples that we had both assembled genomes, as well as Variant of Concern (VOC) PCR results, we  
43 found 100% concordance between these results. Additionally, our assay was able to distinguish between  
44 the Alpha and Gamma variants, which was not possible with our VOC PCR technique. This study  
45 supports future work examining the broader feasibility of SISPA as a diagnostic strategy for the detection  
46 and characterization of viral pathogens.

47

## 48 **Introduction**

49

50 The global COVID-19 pandemic and ensuing public health emergency has underscored the need for  
51 rapid, comprehensive, and cost-effective viral testing strategies to respond effectively to outbreaks and  
52 implement public health policy. COVID-19 disease is caused by severe acute respiratory syndrome

53 coronavirus 2 (SARS-CoV-2); a positive-sense RNA virus from the family *Coronaviridae* (1,2). The  
54 current standard for the diagnosis of many viral infections, including SARS-CoV-2, is based on real-time  
55 qualitative reverse transcription polymerase chain reaction (RT-PCR) assays (3). Due to its low cost,  
56 reliability, and ability to diagnose infection known pathogens, RT-PCR has been at the forefront of viral  
57 diagnostics before and during the COVID-19 pandemic (4). However, this method still requires many  
58 hours of hands-on time by skilled laboratory technicians and is limited in that it only detects a  
59 predetermined number of pathogens that its primers are designed to identify; unknown or unexpected  
60 infectious agents will be missed (5). This is a strong rationale for exploring alternative diagnostic  
61 strategies that can detect known and novel pathogens.

62  
63 Metagenomic next generation sequencing (mNGS) allows all genetic material recovered directly from a  
64 sample to be sequenced and analyzed in a culture-free manner. Sequence-independent single primer  
65 amplification (SISPA) (6) is one such mNGS approach. SISPA enables non-selective reverse transcription  
66 of all extracted RNA in a sample into cDNA and amplifies the reverse transcribed cDNA using random  
67 nonamers tagged to a known primer sequence. This method has been successfully used to detect and  
68 assemble genomes of avian RNA viruses (7), canine distemper virus (8), human enterovirus (9),  
69 chikungunya virus, Ebola virus, hepatitis C virus (10), influenza virus (11), as well as SARS-CoV-2 for a  
70 small number of samples (12,13). Therefore, there is a strong justification for using this approach to  
71 enable detection of pathogenic agents in diagnostic laboratories.

72  
73 SISPA and mNGS have several clear advantages over targeted molecular approaches. mNGS enables  
74 detection of multiple pathogens and co-infection in a clinical sample, as well as potentially providing  
75 information on antimicrobial resistance, virulence, and microbiota-associated dysbiosis at a particular  
76 body site (14,15). Despite the potential advantages of this approach for clinical applications, mNGS  
77 techniques have not yet been widely adopted due to their high-cost, time-intensive sample preparation,  
78 limited access to sequencing infrastructure and lack of robust, easy-to-use and interpret bioinformatics

79 systems (14). Furthermore, the FDA has provided no specific requirements for validation of mNGS-based  
80 diagnostic assays; which has made validation and translation of mNGS tools for detection of  
81 microorganisms challenging for routine clinical microbiology laboratories (15).

82  
83 The Oxford Nanopore Technologies' (ONT) MinION sequencing platform provides a method for high-  
84 throughput, and cost-effective long-read sequencing in a device that fits in the palm of a hand.  
85 Sequencing on the MinION device is also less time-intensive than the Illumina sequencing platform  
86 (14,16). The portability and cost-effectiveness of MinION sequencing makes Nanopore mNGS uniquely  
87 tailored for clinical applications. Despite these advances in long-read clinical sequencing applications, the  
88 field of nanopore clinical metagenomics has been largely unexplored. To date, there are only a few  
89 studies that examine the use of nanopore-based metagenomics for clinical applications (10,11,17,18).

90  
91 Bioinformatic analysis is also a considerable barrier to adoption of mNGS for clinical diagnostics. The  
92 majority of available tools require command line knowledge, significant computing infrastructure, and  
93 experience translating bioinformatic results into actionable results (15,19). As well, traditional short read  
94 analysis services, such as One Codex and IDseq, were not designed or evaluated with third-generation  
95 data (20,21). Several tools have been developed recently to facilitate analysis specifically of nanopore  
96 mNGS data, including BugSeq and EPI2ME (22, <https://epi2me.nanoporetech.com>). BugSeq is a  
97 bioinformatics solution designed for clinical microbiology labs, enabling the end-to-end analysis of  
98 nanopore sequencing data with a graphical user interface and cloud-based data processing. Its analytical  
99 method has been shown to have superior sensitivity and specificity compared to EPI2ME (22), and will  
100 be the primary analysis pipeline used in this study.

101  
102 In this pilot study, we examine the feasibility and performance of a SISPA-based Nanopore mNGS assay  
103 to detect and characterize SARS-CoV-2 from two distinct study populations using the MinION  
104 sequencing device.

105

## 106 **Materials & Methods**

### 107 *Study population and specimen collection:*

108 Clinical specimens were collected from two different populations. First, oropharyngeal swabs were  
109 collected in 2 mL of a guanidinium-based inactivation agent (Prestige Diagnostics) as part of a study  
110 conducted to estimate SARS-CoV-2 infection prevalence in a UK community from April to June 2020.  
111 Swab samples from 2714 individuals from around the greater Oxford area were collected to compare  
112 PCR, serology, and Nanopore sequencing for SARS-CoV-2 infected versus uninfected subjects. A set of  
113 eight SARS-CoV-2 PCR positives or indeterminate samples from this population were included in the  
114 current study. Second, nasopharyngeal swab specimens collected in 3 mL viral transport medium (Yocon  
115 Bio-technology Co. Ltd) were obtained from routine SARS-CoV-2 community testing at Vancouver  
116 General Hospital (VGH) or the BC Centre for Disease Control (BCCDC) (Vancouver, British Columbia,  
117 Canada) (n = 35). RT-PCR testing for COVID-19 was performed for all samples at either the BCCDC  
118 Public Health Laboratory or the medical microbiology laboratory at VGH using either the Roche MagNA  
119 Pure extraction system (Roche Diagnostics, Laval, Canada) in combination with detection of E-gene and  
120 RdRp gene targets, or the Panther Fusion SARS-CoV-2 assay (Hologic Inc., San Diego, CA) detecting  
121 two targets in ORF1ab. Primers for the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) were  
122 developed in-house by the BCCDC Public health laboratory and primers for the E gene were based on the  
123 World Health Organization RT-qPCR protocol (3). The human RNaseP gene was used as an internal  
124 control as suggested by the World Health Organization  
125 ([https://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR\\_SwineH1Assay-  
126 2009\\_20090430.pdf?ua=1](https://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf?ua=1)). A table containing primers and probes used for these assays can be found in  
127 Supplementary Table 1. Additionally, PCR screening for potential variants of concern (VOCs) (Ex.  
128 Alpha, Beta, Gamma, Delta variants) was performed on 11 of the positive swabs obtained from VGH that  
129 were collected during May 2021. Primers and probes were designed to target the N501Y and E484K  
130 mutations (Supplementary Table 2). Swabs were stored at either -80°C for the oropharyngeal swabs or -

131 20°C for the nasopharyngeal swabs. Specimens were chosen to obtain test performance metrics for  
132 Nanopore mNGS across a range of C<sub>t</sub> values (Supplementary Figure 1).

133

134 *RNA Extractions:*

135 Prior to extraction, samples were vortexed and 200 uL of each sample was centrifuged at 16,000g for 3  
136 minutes to pellet host cells. 140 uL of supernatant was aspirated and viral RNA was extracted from the  
137 supernatant using the QIAmp Viral RNA kit (Qiagen) as previously described (11), and eluted in 30 uL  
138 nuclease-free water. Samples were treated with TURBO DNase (Thermo Fisher Scientific) and incubated  
139 at 37°C for 30 minutes, followed by concentration and clean-up with the RNA Clean & Concentrator-5 kit  
140 (Zymo Research); finally, eluting in 8 uL nuclease-free water.

141

142 *SISPA Amplification:*

143 SISPA amplification was performed as described previously (9-13). Briefly, concentrated RNA was  
144 incubated with primer A (100pmol/uL; 5' - GTTTCCTACTGGAGGATA(N<sub>9</sub>) - 3') and then reverse  
145 transcribed using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific). Second strand  
146 synthesis was performed using Sequenase Version 2.0 (Thermo Fisher Scientific), following which,  
147 RNase H was performed to digest any remaining RNA. Random amplification was performed on each  
148 using AccuTaq LA DNA polymerase (Thermo Fisher Scientific) and SISPA primer B (5' -  
149 GTTTCCTACTGGAGGATA - 3'). This reaction underwent PCR using the following conditions: initial  
150 denaturation for 30 seconds at 98°C, followed by 30 cycles of 94°C for 15 seconds, 50°C for 20 seconds,  
151 and 68°C for 2 minutes. A final elongation step of 68°C for 10 minutes was added, prior to a final hold at  
152 4°C. Amplified cDNA was purified using a 1:1 ratio of PCR Clean DX beads (Aline Biosciences) and  
153 eluted in 50 uL nuclease-free water. Amplified cDNA was quantified using a Qubit 4 Fluorometer  
154 (Thermo Fisher Scientific) and fragment lengths were assessed using the TapeStation 2200 automated  
155 electrophoresis platform (Agilent).

156

157 *Library Preparation and MinION Sequencing:*

158 Library preparation was performed using ONT's ligation sequencing kit (SQK-LSK109 or SQK-  
159 LSK110). Multiplexing was performed using the native barcoding expansion 96 kit (EXP-NBD196).  
160 Library preparation was performed according to the manufacturer's instructions, with several key  
161 modifications. DNA repair and end-prep was performed with 1000 fmol of input cDNA and the  
162 incubation times were increased to 30 minutes at 20°C, followed by 30 minutes at 65°C. For the  
163 barcoding reaction 200 fmol of input cDNA was incubated with the native barcodes and Blunt/TA Ligase  
164 Master Mix (New England Biolabs) for 20 minutes at room temperature (15-25°C), followed by 10  
165 minutes at 65°C to improve barcode ligation efficiency with smaller fragments. Up to four clinical  
166 samples (90 fmol/sample) were multiplexed on each minION flowcell, with the addition of a blank viral  
167 transport medium negative control sample to each pooled library. Samples were sequenced on FLO-  
168 MIN106 flowcells on MinION MK1b sequencing devices for 72 hours using MinKNOW (Version 4.2.8,  
169 Oxford Nanopore Technologies) with live basecalling disabled.

170

171 *Sequence Data Analysis:*

172 Raw fast5 files were basecalled using Guppy (Version 5.0.7, Oxford Nanopore Technologies) using the --  
173 *device cuda:0* flag to enable GPU basecalling. Output fastq files were uploaded to BugSeq (version 1.1,  
174 database version: RefSeq on Jan 28, 2021) for metagenomic classification (22), and results classification  
175 results were visualized in ReCentrifuge (23). A representative html file containing an example  
176 visualization output can be found in the supplemental material (Supplementary Data). In brief, reads were  
177 demultiplexed with qcat using default run parameters (enforcing barcodes on both ends, which we have  
178 defined as stringent demultiplexing), followed by quality control with prinseq-lite. Reads shorter than  
179 100bp or those deemed low quality (DUST score less than 7) were discarded. Reads were then classified  
180 against all of the microbial genomes in RefSeq, as well as the human genome and a library of common  
181 contaminants (see 22 for details). Reads classified as SARS-CoV-2 were extracted and used to build a  
182 consensus sequence with Medaka. Bases with less than 20X coverage were masked in accordance with

183 public SARS-CoV-2 sequencing guidelines (<https://www.aphl.org/programs/preparedness/Crisis->  
184 [Management/Documents/APHL-SARS-CoV-2-Sequencing.pdf](https://www.aphl.org/programs/preparedness/Crisis-Management/Documents/APHL-SARS-CoV-2-Sequencing.pdf)). SARS-CoV-2 lineages were assessed  
185 using Pangolin (Version 3.1.5, [github.com/cov-lineages/pangolin](https://github.com/cov-lineages/pangolin)), and phylogenetic analysis was  
186 performed with UShER (24) (Database: GISAID, GenBank, COG-UK and CNCB [2021-07-11]).  
187 Phylogenetic trees were constructed using augur (25), rooted at the SARS-CoV-2 reference sequence, and  
188 visualized in iTOL (26). Antimicrobial resistance genes were detected by aligning reads against the  
189 Resfinder database (27) with minimap2, disabling secondary alignments. Analysis from BugSeq outputs  
190 and visualizations were performed in RStudio (R version 4.1.0) and Python, with all code available at  
191 <https://gitlab.com/bugseq/sars-cov-2-nanopore-mngs-performance> (28).

192

#### 193 *Ethics Approval:*

194 This study obtained research ethics board approval from the University of British Columbia (H20-02152).  
195 Approval for collection of participant data was obtained by the Central University Research Ethics  
196 Committee at the University of Oxford (R69035). Specimens collected as part of routine testing at VGH  
197 and the BCCDC were de-identified and only contained a sample ID number, collection date,  $C_t$ , and VOC  
198 screening result.

199

#### 200 *Data Availability:*

201 Raw FASTQ data has been uploaded to NCBI Bioproject Accession PRJNA752146. Raw reads were  
202 mapped against the human reference genome and transcriptome (Ensembl hg38) using minimap2 (2.20)  
203 (29) and any human reads were removed.

204

#### 205 **Results:**

##### 206 *Sequence data & Sample Descriptions:*

207 Amplified cDNA from a total of 43 patient swabs were sequenced on MinION sequencing devices. Of  
208 these samples, 38 were either positive or had indeterminate results based on SARS-CoV-2 RT-PCR and 5



209 samples had negative RT-PCR results. The 38 positive and indeterminate samples had a mean  $C_t$  value of  
210 27.6 and ranged from 14.7-38.7 (Supplementary Figure 1). Sample collection dates, sample type, total  
211 read counts, as well as dual barcode reads, percent human reads, and SARS-CoV-2 reads per million  
212 reads sequenced (RPM) are present in Table 1. On average, negative controls exhibited a 29.7-fold  
213 decrease in dual barcode reads compared to the average number of dual barcode specimen reads (Mean  
214 dual barcode reads = 20,013, Q1: 158.5, Q3: 17556). SARS-CoV-2 was detected in similar abundance  
215 across our six positive control samples (Mean RPM Dual Barcode:  $103,521 \pm 21,070$ )

216

217 *Sensitivity, Specificity, & Limit of Detection:*

218 We evaluated the test performance of our mNGS assay for detecting SARS-CoV-2. A sample was  
219 considered positive if one or more reads were assigned to SARS-CoV-2. Across all clinical samples, we  
220 detect SARS-CoV-2 with 78.4% (95%CI 62.8%-88.6%) sensitivity and 100% specificity (95%CI 56.6%-  
221 100%) (Table 2). Previous literature has demonstrated decreased sensitivity of mNGS assays above  $C_t$  30  
222 for other viruses (11,30). To assess the dependence of the mNGS assay on  $C_t$  value, we performed a  
223 subgroup analysis on samples above and below SARS-CoV-2  $C_t$  30. For samples with SARS-CoV-2  $C_t$  <  
224 30, sensitivity was 100% (95%CI 84.5%-100%), while for samples with SARS-CoV-2  $C_t$  greater than 30,  
225 sensitivity was 50% (95%CI 27.8%-72.0%).

226

227 We note that two of 11 negative control samples had a single read assigned to SARS-CoV-2. We  
228 investigated these reads (further denoted as read one and two) to identify reasons for false positivity. Both  
229 reads had the expected barcode on both ends of the read as identified by BLAST. The first read exhibited  
230 100% identity over the 24 nucleotide barcode on both ends, and the second read had 100% and 83%  
231 identity over the 24 nucleotide barcode on both ends. We next search these reads against the NCBI  
232 nucleotide database using megaBLAST to assess whether a BugSeq classification error occurred.  
233 However, both reads had top hits that exclusively matched SARS-CoV-2 with greater than 95% identity  
234 over more than 90% of their total length (923 and 1752 bases, respectively). SARS-CoV-2 was detected,

235 despite strict dual barcode demultiplexing and removal reads with improper barcode insertions. Previous  
236 studies have identified barcode crosstalk, ranging from 0.2% to 0.3% of total classified reads, on  
237 Nanopore MinION flowcell results (31,32). When we examined the total SARS-CoV-2 read counts for a  
238 given flowcell on flowcells with false positive negative controls, we saw that one of those flowcells has  
239 the highest total SARS-CoV-2 read count of all flowcells in this study, therefore, we would expect higher  
240 levels of barcode crosstalk for that flowcell (Supplementary Figure 2).

241  
242 We adjusted for barcode crosstalk by controlling for the total number of dual-barcoded SARS-CoV-2  
243 reads on each flowcell. If we assume 0.2% of reads have incorrect barcodes ligated on both ends, and that  
244 these misclassified reads are evenly distributed across all barcodes on the flowcell, we can subtract the  
245 estimated number of misclassified reads from each sample. This correction yielded an acceptable  
246 threshold for classifying specimens as positive or negative. After adjusting for barcode crosstalk in this  
247 manner, we find that seven samples and two negative controls with SARS-CoV-2 reads detected would be  
248 re-classified as negative, and all negative controls are therefore classified correctly. The overall sensitivity  
249 and specificity on clinical samples after adjusting for barcode crosstalk are estimated to be 59.5% (95% CI  
250 43.5%-73.7%) and 100% (56.6%-100%), respectively. Grouping by  $C_t$  value, the sensitivity estimates are  
251 95.2% (95% CI 77.3%-99.2%) and 12.5% (95% CI 3.5%-36.0%) for samples below and above  $C_t$  30,  
252 respectively (Table 3).

253  
254 *RT-qPCR/SISPA Correlation, Genome Coverage, & SARS-CoV-2 Phylogeny:*

255 We assessed the relationship between SARS-CoV-2 RT-PCR  $C_t$  value and SARS-CoV-2 RPM for dual  
256 barcode reads, using stringent demultiplexing analysis parameters. SARS-CoV-2 log-RPM showed a  
257 strong linear association with RT-qPCR  $C_t$  value ( $R^2 = 0.71$ ), with lower  $C_t$  values having a higher RPM  
258 on average (Figure 1). This relationship did not differ by RT-qPCR gene target (E-gene, ORF1ab, or  
259 RdRp) (Supplementary Figure 3). SARS-CoV-2 genome coverage depth showed a similar relationship,  
260 with decreasing coverage depth across the entire genome being associated with increasing  $C_t$  value

261 (Figure 2, Table 4). We produced logistic regression models to assess the probability of attaining greater  
262 than 95% genome coverage at 1X, 20X, or 50X depth of coverage. We found that for every one unit  
263 increase in  $C_t$  value, the odds of recovering a 95% complete genome were 0.765 (95% CI: 0.519, 0.961),  
264 0.263 (95% CI: 0.023, 0.666), or 0.263 (95% CI 0.023, 0.666) on average for coverage depths of 1X,  
265 20X, or 50X, respectively (Figure 3). Interestingly, we did not see any difference in the likelihood of  
266 obtaining 95% coverage for 20X or 50X, despite slight differences in coverage depth for both of these  
267 thresholds (Table 4; Figure 3).

268  
269 SARS-CoV-2 metagenomic reads were used to reconstruct viral genomes. We produced ten complete  
270 (greater than 95% unambiguous bases) and one near-complete consensus genome sequence (greater than  
271 80% unambiguous bases) from our 20 SISPA-positive clinical specimens, masking any bases with less  
272 than 20X coverage. Two partial viral genomes were constructed with 20-25% unambiguous bases.  
273 Pangolin lineage assignment was successful to all complete or near complete genomes; of these five  
274 underwent SARS-CoV-2 VOC PCR testing. All five whole or partial viral genomes were classified as  
275 SARS-CoV-2 lineages concordant with PCR results (Table 5). We also detected an additional VOC in a  
276 sample that did not undergo VOC PCR testing. We also assessed our complete or near-complete  
277 genomes in the context of global SARS-CoV-2 transmission by placing them in a phylogenetic tree  
278 containing over two million publicly available SARS-CoV-2 genomes. The ten complete genomes could  
279 be placed in the global phylogeny with high confidence (only one maximally parsimonious placement),  
280 and the near-complete genome could be placed with lower confidence (nine maximally parsimonious  
281 placements). For ten of 11 genomes derived from metagenomic data, the nearest neighbor in this tree was  
282 a genome derived from the same province of sample collection, British Columbia. Additionally, for 9/11  
283 study genomes, 80% or more of the nearest 50 genomes were derived from British Columbia; for the  
284 remaining two study genomes, 90% or more of the nearest 50 genomes were derived from Canada (Figure  
285 4; Supplementary Figure 4). The UK samples did not yield well covered genomes. Subtrees with nearest  
286 neighbors for all study samples are available in the supplementary material (Supplementary Figure 4).

287

288 *Universal Microbial Detection & Antimicrobial Resistance:*

289 We searched the BugSeq metagenomic output of our clinical specimens for alternative respiratory viruses  
290 or viral or bacterial co-infections. We did not identify any other pathogenic viruses or atypical bacteria  
291 such as *Chlamydia pneumoniae* or *Mycoplasma pneumoniae*. We did identify several members of the  
292 normal nasopharyngeal microbiota, which when found in the lower respiratory tract, may cause disease;  
293 these included two samples with *Moraxella catarrhalis*, seven samples with *Haemophilus influenzae* or  
294 *Haemophilus parainfluenzae*, three samples with *Neisseria meningitidis*, three samples with  
295 *Staphylococcus aureus*, two samples with *Streptococcus pneumoniae* and two samples with *Klebsiella*  
296 *pneumoniae* (Supplementary Table 3). These results are consistent with other metagenomic sequencing  
297 results from the nasopharynx (30). We searched our data for genes conferring antimicrobial resistance,  
298 and identified 10 genes across 6 samples. We found two beta-lactamases in our dataset: *blaTEM-234*, a  
299 class A beta-lactamase which has undetermined spectrum and derived from *Escherichia coli* in sample  
300 P22, as well as *blaOXA-85*, which confers resistance to amoxicillin and amoxicillin-clavulanate, that  
301 derived from *Fusobacterium psuedoperiodonticum* (P9).

302

### 303 **Discussion:**

304 Here, we present a robust analysis detailing the performance of SISPA coupled with Nanopore mNGS to  
305 detect and characterize SARS-CoV-2 from clinical samples. Clinical specimens exhibiting a  $C_t < 30$   
306 performed well. However, test performance declined in specimens exhibiting a  $C_t \geq 30$  from 96.3%  
307 sensitivity for samples below  $C_t$  30 to 12.5% for samples above this cycle threshold. We found an  
308 exponentially declining relationship between RPM and  $C_t$  value, such that the instantaneous change in  
309 read performance was fixed as illustrated in the linear relationship between  $\text{Log}(\text{RPM})$  and  $C_t$  value  
310 (Figure 1). This finding is consistent with other reports on the use of SISPA and Nanopore mNGS for  
311 respiratory infections (11,33). However, our results are not consistent with SISPA and mNGS results  
312 from blood and serum viral diagnostics, where  $C_t$  value did not drastically impact genome coverage (34).

313 These inconsistent results may have been influenced by sample type, sample preparation and the relative  
314 abundance of host nucleic acid in different sample types.

315  
316 Despite limitations in SISPA and Nanopore metagenomic sequencing sensitivity, this approach remains a  
317 valuable technique for the detection of pathogens that are novel, unexpected or uncharacterized, and  
318 therefore unsuitable for targeted approaches such as RT-qPCR or emerging CRISPR-Cas-based  
319 diagnostics, which focus only on known pathogens (35). Unlike these existing diagnostic methods,  
320 Nanopore mNGS can theoretically detect any pathogen and co-infections, characterize changes in the site-  
321 specific microbiota, and capture the carriage of critical virulence or antibiotic-resistant organisms or  
322 genes, all of which can impact patient outcomes. Our approach identified several organisms in the  
323 nasopharyngeal microbiota that may cause disease in the lower respiratory tract, consistent with  
324 sequencing results from a recent study (30). We also did not detect any viral or atypical bacterial co-  
325 infections (Supplementary Table 3), concordant with previous reports of a low prevalence of respiratory  
326 co-infection in COVID-19 positive samples (36-38). In support of this finding, our study regions saw a  
327 dramatic reduction in incidence of other respiratory viruses (eg., influenza and RSV) and bacterial  
328 pathogens over our collection period, thought to be secondary to public health interventions.

329  
330 We additionally assessed the ability of SISPA-based mNGS to classify and assemble complete or partial  
331 SARS-CoV-2 genomes from RT-qPCR positive specimens. This method can perform dual diagnostic and  
332 molecular epidemiology functions. Reliably, we were able to assemble near-complete genomes  
333 (minimum 20X coverage) up to C<sub>t</sub> 25, underscoring the ability of this approach not only to detect  
334 emerging pathogens, but also to characterize them without *a priori* knowledge of a pathogen's genome  
335 sequence. This ability contrasts to amplicon-based sequencing methods, which require the viral sequence  
336 to develop primers (39). We performed lineage typing on metagenomic-derived SARS-CoV-2 genomes  
337 and found perfect concordance with VOC PCR on a small subset of our samples. Moreover, with the  
338 complete and partial genomes we were able to distinguish the P.1 variant from the B.1.351 variant, which

339 the PCR assay was unable to do, as both variants contain the E484K and N501Y mutations in their spike  
340 genes targeted by the PCR assay. Our reconstructed viral genomes were further validated through  
341 phylogenetic analyses, where 10/11 samples that were of British Columbian origin were most closely  
342 related to another British Columbia genome sequence. This highlights the potential of mNGS sequencing  
343 to be an all-in-one assay which detects and characterizes pathogens of interest in near real-time, providing  
344 critical information for clinical care, infection prevention and control and public health interventions .

345  
346 This study examined the methodological feasibility and validity of Nanopore mNGS. We observed false  
347 positive SARS-CoV-2 reads in our negative control samples despite meticulous laboratory preparation,  
348 including performing nucleic acid extractions in a biological safety cabinet, using freshly aliquoted  
349 reagents, decontamination of all surfaces with ethanol and RNaseZap (Thermo Fisher Scientific), and  
350 performing pre-amplification steps in a dedicated PCR area. After investigating these reads, we attribute  
351 them to barcode crosstalk, in accordance with previous studies (30,31). While BugSeq implements  
352 methods to minimize barcode crosstalk from Nanopore sequencing, including requiring barcodes to be  
353 present at both ends of each read and removal of reads with barcodes integrated elsewhere, we developed  
354 a method to adjust the total read counts on a flowcell for barcode crosstalk. These enhancements  
355 improved assay specificity; however, sensitivity is negatively impacted by this read count adjustment.  
356 Interestingly, using the estimated 0.2% expected crosstalk between barcodes based on existing reports in  
357 the literature, we find far fewer false positive reads in our negative controls than would be expected (1  
358 read found in each versus 3 and 107 reads expected). We do note that native barcoding on the Nanopore  
359 platform is not fully optimized, leading to a significant portion of reads with only a single barcode in our  
360 sequencing datasets. This results in a decreased sensitivity, when requiring that barcodes be present on  
361 both read ends. Future advances in sequencing chemistry may reduce the prevalence of barcode crosstalk  
362 while preserving assay sensitivity.

363

364 In addition to employing automated demultiplexing and minimizing barcode crosstalk for Nanopore  
365 mNGS, we validated the BugSeq as a potentially powerful clinical bioinformatics platform and workflow,  
366 including quality control, data visualization, taxonomic classification, consensus sequence generation,  
367 data aggregation, and results reporting. Although a lack of straight-forward and user-friendly  
368 bioinformatics pipelines has long been a deterrent for clinical laboratories implementing NGS and mNGS  
369 methods, our use of BugSeq as a rapid and robust bioinformatics tool has demonstrated the utility of user-  
370 friendly platforms for clinical diagnostics and public health service. Indeed, other groups adopting  
371 MinION sequencers in clinical microbiology laboratories have reached similar conclusions (40,41).

372  
373 Our pilot study has several limitations. Despite the MinION sequencing device providing high-throughput  
374 sequencing data in real-time, this protocol is still significantly more time intensive than RT-PCR as a  
375 diagnostic method, requiring a minimum of 12 hours from sample collection to prepared library, and  
376 another 72 hours of sequencing to reach maximal pathogen detection sensitivity (although results could be  
377 available in as little as 1-2 hours for high viral load samples). The use of liquid handling robots for  
378 automated sample extraction, nucleic acid amplification, and library preparation may aid in  
379 standardization. Additionally, examining the feasibility of a less time intensive library preparation  
380 protocol such as the Rapid Barcoding Kit (Oxford Nanopore Technologies) for this approach will aid in  
381 the optimization and translation of Nanopore mNGS for routine clinical use. The SISPA approach is also  
382 limited in that it performs random amplification of both host and microbial nucleic acids. The high  
383 percentage of host RNA in nasopharyngeal/oropharyngeal swabs limits our ability to rapidly detect  
384 viruses with comparable sensitivity to PCR, requiring deeper sequencing than what is currently feasible  
385 on a MinION. Therefore, this sequencing strategy may not be optimal for samples expected to have very  
386 few viral or bacterial nucleic acids where sensitivity is paramount. We note that while assay sensitivity  
387 has played an important role in public discourse surrounding SARS-CoV-2 testing, there is some data to  
388 suggest that lower viral loads cannot be cultured and are less likely to be transmissible  
389 (<https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf>). This issue



390 is further complicated by the difficulty of employing host nucleic acid removal techniques on low-  
391 biomass samples. Interestingly, the detection of host nucleic acids via mNGS may be useful, as samples  
392 with lower host nucleic acid content have been shown to be associated with higher rates of false-negative  
393 COVID-19 RT-PCR tests, presumably due to sample quality (42). Regardless, methods to enrich for  
394 pathogen sequences or deplete host DNA to increase sensitivity have been examined (43-45), and may  
395 prove useful for future clinical metagenomics studies.

396

397 Our pilot study represents the first analysis of performance and feasibility of SISPA-based Nanopore  
398 mNGS for the detection and characterization of SARS-CoV-2. We were able to successfully detect  
399 SARS-CoV-2 with 100% specificity and near perfect sensitivity for samples below  $C_t$  30 when adjusting  
400 for barcode crossover. We were also able to assemble SARS-CoV-2 genomes and characterize viral  
401 lineages reliably in 10/13 of samples below  $C_t$  25. This assay has the ability not only to detect known  
402 pathogens and co-infections, but can also detect emerging pathogens, assess microbiota states, and  
403 capture resistance and virulence genes. This approach holds promise as a tool for clinical diagnostics and  
404 public health surveillance.

405

406

407

408

409

410

411

412

413

414

415



416 **References:**

- 417 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML,  
418 Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. 2020. A new  
419 coronavirus associated with human respiratory disease in China. *Nature* 579:265–269.
- 420 2. Tavares R de CA, Mahadeshwar G, Pyle AM. 2020. The global and local distribution of RNA  
421 structure throughout the SARS-CoV-2 genome. *J Virol* <https://doi.org/10.1101/2020.07.06.190660>.
- 422 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,  
423 Schneider J, Luisa Schmidt M, GJC Mulders D, Haagmans BL, van der Veer B, van den Brink S,  
424 Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,  
425 Koopmans MP, Drosten C, Victor CM, Olfert L, Marco K, Richard M, Adam M, Daniel CK, Tobias  
426 B, Sebastian B, Julia S, Marie Luisa S, Daphne GJC M, Bart HL, der Veer Bas V, den Brink Sharon  
427 V, Lisa W, Gabriel G, Jean-Louis R, Joanna E, Maria Z, Malik P, Herman G, Chantal R. 2020.  
428 Detection of 2019 -nCoV by RT-PCR. *Euro Surveill* 25:1–8.
- 429 4. Li X, Geng M, Peng Y, Meng L, Lu S. 2020. Molecular immune pathogenesis and diagnosis of  
430 COVID-19. *J Pharm Anal* 10:102–108.
- 431 5. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. 2020. Overcoming the bottleneck  
432 to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection.  
433 *Cold Spring Harb Lab Press* 26:771–783.
- 434 6. Reyes GR, Kim JP. Sequence-independent, single-primer amplification (SISPA) of complex DNA  
435 populations. *Mol Cell probes* 5:473–481.
- 436 7. Chrzastek K, Lee D hun, Smith D, Sharma P, Suarez DL, Pantin-Jackwood M, Kapczynski DR.  
437 2017. Use of Sequence-Independent, Single-Primer-Amplification (SISPA) for rapid detection,  
438 identification, and characterization of avian RNA viruses. *Virology* 509:159–166.

- 439 8. Peserico A, Marcacci M, Malatesta D, Di Domenico M, Pratelli A, Mangone I, D’Alterio N,  
440 Pizzurro F, Cirone F, Zaccaria G, Cammà C, Lorusso A. 2019. Diagnosis and characterization of  
441 canine distemper virus through sequencing by MinION nanopore technology. *Sci Rep* 9:1–9.
- 442 9. Wollants E, Maes P, Merino M, Bloemen M, Van Ranst M, Vanmechelen B. 2020. First genomic  
443 characterization of a Belgian Enterovirus C104 using sequence-independent Nanopore sequencing.  
444 *Infect Genet Evol* 81:104267.
- 445 10. Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres V, Stryke D, Bouquet J, Somasekar  
446 S, Linnen JM, Dodd R, Mulembakani P, Schneider BS, Muyembe-Tamfum JJ, Stramer SL, Chiu  
447 CY. 2015. Rapid metagenomic identification of viral pathogens in clinical samples by real-time  
448 nanopore sequencing analysis. *Genome Med* 7:1–13.
- 449 11. Lewandowski K, Xu Y, Pullan ST, Lumley SF, Foster D, Sanderson N, Vaughan A, Morgan M,  
450 Bright N, Kavanagh J, Vipond R, Carroll M, Marriott AC, Gooch KE, Andersson M, Jeffery K, Peto  
451 TEA, Crook DW, Sarah Walker A, Matthews PC. 2020. Metagenomic nanopore sequencing of  
452 influenza virus direct from clinical respiratory samples. *J Clin Microbiol* 58:1–15.
- 453 12. Moreno GK, Braun KM, Halfmann PJ, Prall TM, Riemersma KK, Haj AK, Lalli J, Florek KR,  
454 Kawaoka Y, Friedrich TC, O’Connor DH. 2020. Limited SARS-CoV-2 diversity within hosts and  
455 following passage in cell culture. *bioRxiv* 2020.04.20.051011.
- 456 13. Moore SC, Penrice-randal R, Alruwaili M, Dong X, Pullan ST, Carter DP, Bewley K, Zhao Q, Sun  
457 Y, Hartley C, Zhou E, Solomon T, Beadsworth MBJ, Bogaert D, Crook DW, Matthews DA,  
458 Andrew D, Mahmood Z, Aljabr W, Druce J, Vipond RT. 2020. Amplicon based MinION  
459 sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from  
460 patients with COVID-19. *medRxiv* 2020.03.05.20032011.
- 461 14. Petersen LM, Martin IW, Moschetti WE, Kershaw CM, Tsongalis GJ. 2020. Third-Generation  
462 Sequencing in the Clinical Laboratory : Exploring the Advantages and Challenges of Nanopore  
463 Sequencing. *J Clin Microbiol* 58:1–10.

- 464 15. Chiu CY, Miller SA. 2019. Clinical metagenomics. *Nat Rev Genet* 20:341–355.
- 465 16. Forbes JD, Knox NC, Peterson C, Reimer AR. 2018. Highlighting Clinical Metagenomics for  
466 Enhanced Diagnostic Decision-making : A Step Towards Wider Implementation. *Comput Struct*  
467 *Biotechnol J* 16:108–120.
- 468 17. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, Turner  
469 DJ, Wain J, Leggett RM, Livermore DM, O’Grady J. 2019. Nanopore metagenomics enables rapid  
470 clinical diagnosis of bacterial lower respiratory infection. *Nat Biotechnol* 37:783–792.
- 471 18. Schmidt K, Mwaigwisya S, Crossman LC, Doumith M, Munroe D, Pires C, M. Khan A, Woodford  
472 N, Saunders NJ, Wain J, O’Grady J, Livermore DM. 2017. Identification of bacterial pathogens and  
473 antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing. *J*  
474 *Antimicrob Chemother* 72:104–114.
- 475 19. Chiang AD, Dekker JP. 2020. From the pipeline to the bedside: Advances and challenges in clinical  
476 metagenomics. *J Infect Dis* 221:S331–S340.
- 477 20. Minot S, Krumm N, Greenfield N. 2015. One Codex: A Sensitive and Accurate Data Platform for  
478 Genomic Microbial Identification. *bioRxiv* 027607.
- 479 21. Kalantar KL, Carvalho T, De Bourcy CFA, Dimitrov B, Dingle G, Egger R, Han J, Holmes OB,  
480 Juan YF, King R, Kislyuk A, Lin MF, Mariano M, Morse T, Reynoso L V., Cruz DR, Sheu J, Tang  
481 J, Wang J, Zhang MA, Zhong E, Ahyong V, Lay S, Chea S, Bohl JA, Manning JE, Tato CM, DeRisi  
482 JL. 2021. IDseq-An open source cloud-based pipeline and analysis service for metagenomic  
483 pathogen detection and monitoring. *Gigascience* 9:1–14.
- 484 22. Fan J, Huang S, Chorlton SD. 2021. BugSeq: a highly accurate cloud platform for long-read  
485 metagenomic analyses. *BMC Bioinformatics* 22:1–12.
- 486 23. Martí JM. 2019. Recentrifuge: Robust comparative analysis and contamination removal for  
487 metagenomics. *PLoS Comput Biol* 15:1–24.

- 488 24. Turakhia Y, Thornlow B, Hinrichs AS, De Maio N, Gozashti L, Lanfear R, Haussler D, Corbett-  
489 Detig R. 2021. Ultrafast Sample placement on Existing tRees (UShER) enables real-time  
490 phylogenetics for the SARS-CoV-2 pandemic. *Nat Genet* 53:809–816.
- 491 25. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher  
492 RA. 2018. NextStrain: Real-time tracking of pathogen evolution. *Bioinformatics* 34:4121–4123.
- 493 26. Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the display and  
494 annotation of phylogenetic and other trees. *Nucleic Acids Res* 44:W242–W245.
- 495 27. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,  
496 Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl  
497 K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett  
498 NA, Kempf I, Nykäsenoja S, Olkkola S, Wiczorek K, Amaro A, Clemente L, Mossong J, Losch S,  
499 Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from  
500 genotypes. *J Antimicrob Chemother* 75:3491–3500.
- 501 28. RStudio Team (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA URL  
502 <http://www.rstudio.com/>.
- 503 29. Li H. 2018. Minimap2: Pairwise alignment for nucleotide sequences. *Bioinformatics* 34:3094–3100.
- 504 30. Xu Y, Lewandowski K, Downs L, Kavanagh J, Hender T, Lumley S, Jeffery K, Foster D, Sanderson  
505 N, Vaughan A, Morgan M, Vipond R, Carroll M, Peto T, Crook D, Walker AS, Matthews P, Pullan  
506 S. 2021. Nanopore metagenomic sequencing of influenza virus directly from respiratory samples:  
507 diagnosis, drug resistance and nosocomial transmission. *Eurosurveillance* 26:1–12.
- 508 31. Xu Y, Lewandowski K, Lumley S, Pullan S, Vipond R, Carroll M, Foster D, Matthews PC, Peto T,  
509 Crook D. 2018. Detection of viral pathogens with multiplex nanopore MinION sequencing: Be  
510 careful with cross-Talk. *Front Microbiol* 9:1–7.

- 511 32. Wick RR, Judd LM, Holt KE. 2018. Deepbiner: Demultiplexing barcoded Oxford Nanopore reads  
512 with deep convolutional neural networks. *PLoS Comput. Biol.* doi.org/10.1371/journal.pcbi.1006583
- 513 33. Klaudia Chrzastek, Chandana Tennakoon, Dagmara Bialy, Graham Freimanis JF and HS. 2021. A  
514 random priming amplification method for whole genome sequencing of SARS-CoV-2 and H1N1  
515 influenza A virus. *bioRxiv* 2021.06.25.449750.
- 516 34. Kafetzopoulou LE, Efthymiadis K, Lewandowski K, Crook A, Carter D, Osborne J, Aarons E,  
517 Hewson R, Hiscox JA, Carroll MW, Vipond R, Pullan ST. 2018. Assessment of metagenomic  
518 Nanopore and Illumina sequencing for recovering whole genome sequences of chikungunya and  
519 dengue viruses directly from clinical samples. *Eurosurveillance* 23:1–13.
- 520 35. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. 2019. SHERLOCK: nucleic acid  
521 detection with CRISPR nucleases. *Nat Protoc* 14:2986–3012.
- 522 36. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JPR, Daneman  
523 N. 2020. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid  
524 review and meta-analysis. *Clin Microbiol Infect* 26:1622–1629.
- 525 37. Lansbury L, Lim B, Baskaran V, Lim WS. 2020. Co-infections in people with COVID-19: a  
526 systematic review and meta-analysis. *J Infect* 81:266–275.
- 527 38. Karaba SM, Jones G, Hessel T, Smith LL, Avery R, Dzintars K, Salinas AB, Keller SC, Townsend  
528 JL, Klein E, Amoah J, Garibaldi BT, Cosgrove SE, Fabre V. 2021. Prevalence of co-infection at the  
529 time of hospital admission in COVID-19 Patients, A multicenter study. *Open Forum Infect Dis* 8:1–  
530 7.
- 531 39. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, Oliveira G, Robles-  
532 Sikisaka R, Rogers TF, Beutler NA, Burton DR, Lewis-Ximenez LL, Jesus JG de, Giovanetti M,  
533 Hill S, Black A, Bedford T, Carroll MW, Nunes M, Jr LCA, Sabino EC, Baylis SA, Faria N, Loose  
534 M, Simpson JT, Pybus OG, Andersen KG, Loman NJ. 2017. Zika and other virus genomes directly  
535 from clinical samples. *Nat Protoc* 12:1261–1276.

- 536 40. Chorlton SD, Ritchie G, Lawson T, McLachlan E, Romney MG, Matic N, Lowe CF. 2021. Next-  
537 generation sequencing for cytomegalovirus antiviral resistance genotyping in a clinical virology  
538 laboratory. *Antiviral Res* 192:105123.
- 539 41. Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, Young M, Dong W, Brumme ZL,  
540 Brumme CJ, Leung V, Romney MG. 2021. Rapid detection of SARS-CoV-2 variants of concern,  
541 including B.1.1.28/P.1, British Columbia, Canada. *Emerg Infect Dis* 27:1673–1676.
- 542 42. Kinloch NN, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, Brad Jones R, Montaner JSG,  
543 Leung V, Romney MG, Stefanovic A, Matic N, Lowe CF, Brumme ZL. 2020. Suboptimal  
544 biological sampling as a probable cause of false-negative COVID-19 diagnostic test results. *J Infect*  
545 *Dis* 222:899–902.
- 546 43. Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, Yagi S, Mbala-Kingebeni P,  
547 Kapetshi J, Ahuka-Mundeke S, Muyembe-Tamfum JJ, Ahmed AA, Ganesh V, Tamhankar M,  
548 Patterson JL, Ndembi N, Mbanya D, Kaptue L, McArthur C, Muñoz-Medina JE, Gonzalez-Bonilla  
549 CR, López S, Arias CF, Arevalo S, Miller S, Stone M, Busch M, Hsieh K, Messenger S, Wadford  
550 DA, Rodgers M, Cloherty G, Faria NR, Thézé J, Pybus OG, Neto Z, Morais J, Taveira N, R. Hackett  
551 J, Chiu CY. 2020. Metagenomic sequencing with spiked primer enrichment for viral diagnostics and  
552 genomic surveillance. *Nat Microbiol* 5:443–454.
- 553 44. Yap M, Feehily C, Walsh CJ, Fenelon M, Murphy EF, McAuliffe FM, van Sinderen D, O’Toole  
554 PW, O’Sullivan O, Cotter PD. 2020. Evaluation of methods for the reduction of contaminating host  
555 reads when performing shotgun metagenomic sequencing of the milk microbiome. *Sci Rep* 10:1–11.
- 556 45. Ji XC, Zhou LF, Li CY, Shi YJ, Wu ML, Zhang Y, Fei XF, Zhao G. 2020. Reduction of Human  
557 DNA Contamination in Clinical Cerebrospinal Fluid Specimens Improves the Sensitivity of  
558 Metagenomic Next-Generation Sequencing. *J Mol Neurosci* 70:659–666.

559

560

561 **Table 1: Study sample descriptions and sequencing results**

| Study ID | Collection Location | Swab Type | Collection Date | Ct Value      | Gene   | Kit        | Reads     | Dual Barcode | % Human | RPM (Dual Barcode) |
|----------|---------------------|-----------|-----------------|---------------|--------|------------|-----------|--------------|---------|--------------------|
| P1       | VGH                 | NPS       | Fall 2020       | 37.1          | ORF1ab | SQK-LSK109 | 2,592,365 | 580,829      | 90      | 3,030.15           |
| P2       | VGH                 | NPS       | Fall 2020       | 24.1          | ORF1ab | SQK-LSK109 | 2,196,488 | 425,936      | 50      | 62,401.39          |
| P3       | VGH                 | NPS       | Fall 2020       | 14.7          | ORF1ab | SQK-LSK109 | 1,480,039 | 268,331      | 8       | 889,826.37         |
| P4       | Oxford              | OPS       | Spring 2020     | 25.4          | E-gene | SQK-LSK109 | 1,681,970 | 194,567      | 62      | 3,135.17           |
| P5       | Oxford              | OPS       | Spring 2020     | 29.9          | E-gene | SQK-LSK109 | 1,487,346 | 369,374      | 81      | 2.71               |
| P6       | Oxford              | OPS       | Spring 2020     | 34.1          | E-gene | SQK-LSK109 | 1,484,871 | 224,739      | 39      | 0                  |
| P7       | Oxford              | OPS       | Spring 2020     | 35.4          | E-gene | SQK-LSK109 | 1,871,165 | 315,162      | 88      | 0                  |
| P8       | Oxford              | OPS       | Spring 2020     | 38.7          | E-gene | SQK-LSK109 | 4,892,596 | 1,648,997    | 79      | 0                  |
| P9       | Oxford              | OPS       | Spring 2020     | 31.7          | E-gene | SQK-LSK109 | 3,095,244 | 853,190      | 54      | 0                  |
| P10      | Oxford              | OPS       | Spring 2020     | Indeterminate | E-gene | SQK-LSK109 | 3,195,376 | 1,209,061    | 65      | 0                  |
| P11      | Oxford              | OPS       | Spring 2020     | Indeterminate | E-gene | SQK-LSK109 | 2,642,491 | 758,333      | 28      | 0                  |
| P12      | BCCDC               | NPS       | Fall 2020       | 36.13         | E-gene | SQK-LSK110 | 1,894,335 | 425,729      | 91      | 2.35               |
| P13      | BCCDC               | NPS       | Fall 2020       | 35.21         | E-gene | SQK-LSK110 | 2,612,555 | 636,570      | 0.2     | 0                  |
| P14      | BCCDC               | NPS       | Fall 2020       | 33.33         | E-gene | SQK-LSK110 | 3,335,378 | 794,876      | 16      | 1.26               |
| P15      | BCCDC               | NPS       | Fall 2020       | 33.73         | E-gene | SQK-LSK110 | 3,689,514 | 897,886      | 98      | 0                  |
| P16      | BCCDC               | NPS       | Fall 2020       | 33.63         | E-gene | SQK-LSK110 | 2,301,355 | 593,209      | 80      | 5.06               |
| P17      | BCCDC               | NPS       | Fall 2020       | Indeterminate | NA     | SQK-LSK110 | 1,412,609 | 384,971      | 10      | 38.96              |
| P18      | BCCDC               | NPS       | Fall 2020       | Indeterminate | NA     | SQK-LSK110 | 1,269,020 | 256,134      | 92      | 0                  |
| P19      | BCCDC               | NPS       | Fall 2020       | 36.33         | E-gene | SQK-LSK110 | 2,588,988 | 744,812      | 82      | 0                  |
| P20      | VGH                 | NPS       | Spring 2021     | 35.6          | ORF1ab | SQK-LSK110 | 1,535,450 | 431,421      | 48      | 2.32               |
| P21      | VGH                 | NPS       | Spring 2021     | 34.3          | ORF1ab | SQK-LSK110 | 1,553,510 | 411,279      | 37      | 2.43               |
| P22      | VGH                 | NPS       | Spring 2021     | 33.7          | ORF1ab | SQK-LSK110 | 1,206,439 | 328,369      | 47      | 3.05               |
| P23      | VGH                 | NPS       | Spring 2021     | 21.4          | ORF1ab | SQK-LSK110 | 1,584,504 | 499,025      | 7       | 17,462.05          |
| P24      | VGH                 | NPS       | May 2021        | 15.5          | ORF1ab | SQK-LSK110 | 2,875,078 | 728,905      | 84      | 58,192.77          |
| P25      | VGH                 | NPS       | May 2021        | 16.1          | ORF1ab | SQK-LSK110 | 2,184,440 | 484,358      | 87      | 68,748.74          |
| P26      | VGH                 | NPS       | May 2021        | 16.1          | ORF1ab | SQK-LSK110 | 968,712   | 301,091      | 49      | 493,422.25         |
| P27      | VGH                 | NPS       | May 2021        | 17            | ORF1ab | SQK-LSK110 | 2,550,631 | 737,603      | 81      | 60,411.90          |
| P28      | VGH                 | NPS       | May 2021        | 17.7          | ORF1ab | SQK-LSK110 | 2,151,872 | 503,298      | 87      | 22,088.31          |
| P29      | VGH                 | NPS       | May 2021        | 20            | ORF1ab | SQK-LSK110 | 993,047   | 212,823      | 77      | 47,057.88          |
| P30      | VGH                 | NPS       | Dec 2020        | 22            | E-gene | SQK-LSK110 | 707,288   | 253,025      | 81      | 171,129.34         |
| P31      | VGH                 | NPS       | May 2021        | 22.8          | ORF1ab | SQK-LSK110 | 2,009,926 | 456,803      | 98      | 1,136.16           |
| P32      | VGH                 | NPS       | May 2021        | 23.5          | ORF1ab | SQK-LSK110 | 3,173,498 | 687,623      | 99      | 373.75             |
| P33      | VGH                 | NPS       | May 2021        | 24.4          | ORF1ab | SQK-LSK110 | 1,597,376 | 239,837      | 85      | 1,054.88           |
| P34      | VGH                 | NPS       | May 2021        | 25.5          | ORF1ab | SQK-LSK110 | 1,103,117 | 283,010      | 99      | 38.87              |
| P35      | VGH                 | NPS       | May 2021        | 27.3          | ORF1ab | SQK-LSK110 | 3,325,162 | 1,042,089    | 95      | 2.88               |
| P36      | VGH                 | NPS       | May 2021        | 27.7          | ORF1ab | SQK-LSK110 | 1,374,869 | 322,646      | 87      | 27.89              |
| P37      | VGH                 | NPS       | July 2020       | 28            | E-gene | SQK-LSK110 | 1,365,733 | 278,532      | 86      | 240.55             |
| P38      | VGH                 | NPS       | May 2021        | 30.6          | ORF1ab | SQK-LSK110 | 4,458,073 | 1,335,187    | 98      | 49.43              |
| N1       | VGH                 | NPS       | May 2021        | NA            | NA     | SQK-LSK110 | 1,803,891 | 521,584      | 96      | 0                  |
| N2       | VGH                 | NPS       | May 2021        | NA            | NA     | SQK-LSK110 | 1,932,656 | 645,041      | 96      | 0                  |
| N3       | VGH                 | NPS       | May 2021        | NA            | NA     | SQK-LSK110 | 3,421,518 | 1,053,199    | 98      | 0                  |
| N4       | VGH                 | NPS       | May 2021        | NA            | NA     | SQK-LSK110 | 4,947,322 | 1,539,940    | 75      | 0                  |
| N5       | VGH                 | NPS       | May 2021        | NA            | NA     | SQK-LSK110 | 1,386,059 | 722,140      | 90      | 0                  |

562 **Table 2:** Overall sample classification, before adjustment for barcode crosstalk

|                      |       | <b>Positive by mNGS</b> | <b>Negative by mNGS</b> | <b>Sum</b> |
|----------------------|-------|-------------------------|-------------------------|------------|
| <b>True positive</b> | Ct≤30 | 21                      | 0                       | 21         |
|                      | Ct>30 | 8                       | 8                       | 16         |
| <b>True negative</b> |       | 0                       | 5                       | 5          |
| <b>Sum</b>           |       | 29                      | 13                      |            |

563

564 **Table 3:** Overall sample classification, after adjustment for barcode crosstalk

|                      |       | <b>Positive by mNGS</b> | <b>Negative by mNGS</b> | <b>Sum</b> |
|----------------------|-------|-------------------------|-------------------------|------------|
| <b>True positive</b> | Ct≤30 | 20                      | 1                       | 21         |
|                      | Ct>30 | 2                       | 14                      | 16         |
| <b>True negative</b> |       | 0                       | 5                       | 5          |
| <b>Sum</b>           |       | 22                      | 20                      |            |

565

566

567

568

569

570

571

572

573

574



575 **Table 4:** Percent SARS-CoV-2 genome coverage for samples classified as mNGS SARS-CoV-2 positive  
576 following 0.2% crosstalk correction

| <b>Study ID</b> | <b>Ct Value</b> | <b>RPM (Dual Barcode)</b> | <b>50X Coverage</b> | <b>20X Coverage</b> | <b>1X Coverage</b> |
|-----------------|-----------------|---------------------------|---------------------|---------------------|--------------------|
| P1              | 37.1            | 3,030.15                  | 26.25               | 80.09               | 99.85              |
| P2              | 24.1            | 62,401.39                 | 99.85               | 99.94               | 100                |
| P3              | 14.7            | 889,826.37                | 99.98               | 100                 | 100                |
| P4              | 25.4            | 3,135.17                  | 1.57                | 23.71               | 100                |
| P23             | 21.4            | 17,462.05                 | 98.85               | 99.78               | 99.95              |
| P24             | 15.5            | 58,192.77                 | 99.8                | 99.91               | 100                |
| P25             | 16.1            | 68,748.74                 | 99.85               | 99.97               | 100                |
| P26             | 16.1            | 493,422.25                | 99.99               | 100                 | 100                |
| P27             | 17              | 60,411.90                 | 99.81               | 99.89               | 100                |
| P28             | 17.7            | 22,088.31                 | 99.78               | 99.79               | 100                |
| P29             | 20              | 47,057.88                 | 99.59               | 99.75               | 100                |
| P30             | 22              | 171,129.34                | 99.8                | 99.85               | 100                |
| P31             | 22.8            | 1,136.16                  | 0                   | 20.01               | 99.99              |
| P32             | 23.5            | 373.75                    | 0                   | 3.87                | 98.94              |
| P33             | 24.4            | 1,054.88                  | 0                   | 0                   | 98.74              |
| P34             | 25.5            | 38.87                     | 0                   | 0                   | 15.25              |
| P35             | 27.3            | 2.88                      | 0                   | 0                   | 3.63               |
| P36             | 27.7            | 27.89                     | 0                   | 0.3                 | 3.85               |
| P37             | 28              | 240.55                    | 0                   | 0.07                | 47.25              |
| P38             | 30.6            | 49.43                     | 0                   | 0                   | 72.79              |

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591


592 **Table 5: SARS-CoV-2 Variant of Concern PCR and Pangolin classification results**

| Study ID | RPM (Dual Barcode) | VOC PCR Result  | Pangolin Lineage (Scorpio Call) |
|----------|--------------------|---|---------------------------------|
| P1       | 3,030.15           | Not Performed   | B.1.2                           |
| P2       | 62,401.39          | Not Performed   | B.1.128                         |
| P3       | 889,826.37         | Not Performed   | B.1.2                           |
| P4       | 3,135.17           | Not Performed   | None                            |
| P23      | 17,462.05          | Not Performed   | B.1.2                           |
| P24      | 58,192.77          | Not Performed   | P.1 (Gamma)                     |
| P25      | 68,748.74          | Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.                          | P.1 (Gamma)                     |
| P26      | 493,422.25         | Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected. | B.1.1.7 (Alpha)                 |
| P27      | 60,411.90          | Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected. | B.1.1.7 (Alpha)                 |
| P28      | 22,088.31          | Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.                          | P.1 (Gamma)                     |
| P29      | 47,057.88          | Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected. | B.1.1.7 (Alpha)                 |
| P30      | 171,129.34         | Not Performed   | B.1.36.36                       |
| P31      | 1,136.16           | Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.                          | None                            |
| P32      | 373.75             | Negative. No Spike gene N501Y or E484K mutations detected by NAT.   | None                            |
| P33      | 1,054.88           | Presumptive Positive B.1.1.7 Variant of Concern. Spike gene N501Y mutation DETECTED by NAT. No E484K mutation detected. | None                            |
| P34      | 38.87              | Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.                          | None                            |
| P35      | 2.88               | Not Performed   | None                            |
| P36      | 27.89              | Presumptive Positive Variant of Concern. Spike gene N501Y and E484K mutations DETECTED by NAT.                          | None                            |
| P37      | 240.55             | Not Performed   | None                            |
| P38      | 49.43              | Negative. No Spike gene N501Y or E484K mutations detected by NAT.   | None                            |

593

594

595



596

597 **Figure 1:** Log SARS-CoV-2 reads per million reads sequenced across  $C_t$  value (E gene or ORF1ab) for  
598 all RT-qPCR positive samples. 95% confidence intervals for the linear regression line are shaded in grey.

599 Coefficient of determination = 0.71.

600


601

602



603  
604 **Figure 2:** Coverage depth for samples classified as positive by our classifier with log depth of coverage  
605 on the y-axis and SARS-CoV-2 reference genome position on the x-axis

606  
607  
608  
609  
610  
611  
612  
613  
614



615


616 **Figure 3:** Probability of obtaining greater than 95% genome coverage (1 = Yes, 0 = No) for RT-qPCR  
617 positive study samples across  $C_t$  value for **a.** 1x, **b.** 20x, and **c.** 50x genome coverage. Logistic regression  
618 models are represented in blue.

619

620

621

622



623  
624 **Figure 4:** Study samples (marked as P1, P2, etc.) and their nearest three neighbors from all publicly  
625 available SARS-CoV-2 sequences  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635